Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03529513 · ClinicalTrials.gov registry record
Medibio DDA Confirmatory Performance Study
A clinical trial, sponsored by Medibio Limited.
- Completed
- Registry status
- 234
- Enrollment target
NCT03529513: Completed study, sponsored by Medibio Limited.
NCT03529513 is a clinical trial that has completed, run by Medibio Limited. The registered enrollment target is 234 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03529513 has completed, sponsored by Medibio Limited.
- COMPLETED
- Registry status
- 234 participants
- Enrollment target
Study Summary
This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.
Primary Outcome
The Medibio Algorithm will process data from subject 24-hour ECG data recordings.
Interventions
- DIAGNOSTIC_TEST Medibio Depression Diagnostic Aid
- DIAGNOSTIC_TEST Mini International Neuropsychiatric Interview
- DIAGNOSTIC_TEST Hamilton Rating Scale for Depression - 17 Item
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2018-05-04 |
What the finished NCT03529513 record still lists
NCT03529513 is an observational study that tracks outcomes without assigning an intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Medibio Depression Diagnostic Aid is the first listed.
NCT03529513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03529513 about?
NCT03529513 is a clinical study titled "Medibio DDA Confirmatory Performance Study". This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.
What is the current status of trial NCT03529513?
This trial is currently completed. The enrollment target is 234 participants. The study started on 2017-08-18. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT03529513?
The interventions under investigation include: Medibio Depression Diagnostic Aid (DIAGNOSTIC_TEST), Mini International Neuropsychiatric Interview (DIAGNOSTIC_TEST), Hamilton Rating Scale for Depression - 17 Item (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03529513?
This trial is sponsored by Medibio Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI